Table 3 Classification results per group.
From: Pseudoprogression prediction in high grade primary CNS tumors by use of radiomics
Number of features | Test data | Development data | Independent validation data | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AUC (%) | Sens. (%) | Spec. (%) | Acc. (%) | AUC (%) | Sens. (%) | Spec. (%) | Acc. (%) | AUC (%) | Sens. (%) | Spec. (%) | Acc. (%) | |
1 | 69.50 | 52.94 | 75.29 | 64.32 | 82.55 | 61.58 | 88.70 | 75.40 | 65.46 | 62.50 | 67.15 | 64.92 |
2 | 74.98 | 63.18 | 77.72 | 70.59 | 86.06 | 69.38 | 83.22 | 76.43 | 66.16 | 53.58 | 73.00 | 63.68 |
3 | 77.26 | 65.65 | 76.10 | 70.97 | 91.00 | 79.04 | 87.61 | 83.41 | 66.59 | 68.33 | 72.92 | 70.72 |
4 | 77.79 | 66.02 | 75.37 | 70.78 | 91.74 | 81.81 | 89.13 | 85.54 | 72.51 | 70.00 | 78.46 | 74.40 |
5 | 78.04 | 66.39 | 77.21 | 71.90 | 91.50 | 80.25 | 88.98 | 84.70 | 73.91 | 74.17 | 75.38 | 74.80 |
6 | 78.51 | 66.26 | 78.31 | 72.40 | 91.49 | 79.92 | 88.61 | 84.35 | 72.87 | 71.75 | 80.00 | 76.04 |
7 | 77.75 | 65.90 | 77.89 | 72.01 | 91.90 | 80.98 | 89.65 | 85.40 | 73.89 | 72.75 | 82.23 | 77.68 |
8 | 78.06 | 68.21 | 76.04 | 72.20 | 94.02 | 83.65 | 91.93 | 87.87 | 75.28 | 73.42 | 82.31 | 78.04 |
9 | 76.63 | 66.47 | 75.22 | 70.92 | 93.71 | 83.17 | 91.78 | 87.56 | 76.72 | 71.75 | 80.85 | 76.48 |
10 | 77.09 | 67.44 | 74.38 | 70.98 | 95.44 | 85.83 | 92.96 | 89.46 | 78.21 | 71.67 | 82.85 | 77.48 |
11 | 75.88 | 66.36 | 72.95 | 69.72 | 95.21 | 86.35 | 93.02 | 89.75 | 77.42 | 71.08 | 81.54 | 76.52 |
12 | 75.12 | 65.31 | 72.80 | 69.13 | 94.04 | 84.04 | 91.37 | 87.77 | 76.49 | 69.83 | 80.38 | 75.32 |
13 | 75.26 | 65.69 | 71.94 | 68.87 | 96.09 | 88.02 | 94.06 | 91.09 | 75.37 | 69.58 | 82.15 | 76.12 |
14 | 76.28 | 66.39 | 72.09 | 69.30 | 97.19 | 90.63 | 95.69 | 93.21 | 75.13 | 69.00 | 82.85 | 76.20 |
15 | 75.29 | 64.89 | 72.09 | 68.56 | 96.03 | 89.13 | 94.50 | 91.87 | 74.60 | 68.00 | 80.54 | 74.52 |
